Influenza Antibody CDR Optimization for Intranuclear Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies for detecting influenza viruses lack specificity and efficiency in binding to intranuclear proteins, particularly for type-A influenza viruses, and often exhibit cross-reactivity with other viral subtypes, limiting their effectiveness in detection methods.
Innovation Solution
A novel antibody with a specific amino acid sequence (N-FR1-CDR1-FR2-CDR2-CDR3-FR4-C) is developed, comprising CDR1 (GFTFSNY), CDR2 (NSGGTG), and CDR3 (RVDGRVLSTIVVSYDY) regions, which effectively binds to intranuclear proteins of type-A influenza viruses, minimizing cross-reactivity with other viral subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibodies are used for detecting influenza viruses, then detection capability is provided, but specificity and binding affinity to intranuclear proteins are insufficient and cross-reactivity with other viral subtypes occurs
Solution Approach 1:
The patent applies parameter changes by precisely defining and optimizing the amino acid sequences in the complementarity determining regions (CDR1, CDR2, CDR3) of the antibody. By changing the specific amino acid parameters in these critical regions, the antibody achieves high specificity for type-A influenza virus intranuclear proteins while minimizing cross-reactivity with other viral subtypes, directly resolving the contradiction between detection precision and reliability.
2Strength
If conventional antibodies are used for detecting influenza viruses, then detection is enabled, but binding affinity to intranuclear proteins is insufficient
Solution Approach 1:
The patent applies local quality by focusing the optimization on specific local regions (CDR1, CDR2, CDR3) of the antibody molecule rather than the entire structure. By enhancing the binding affinity at these critical local sites that contact the intranuclear protein, the antibody achieves strong and specific binding, thereby improving both binding affinity and detection accuracy simultaneously.
Data Source
AI summary
The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains:N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-CwhereinFR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence;the CDR1 includes an amino acid sequence represented by GFTFSNY (SEQ ID NO: 1);the CDR2 includes an amino acid sequence represented by NSGGTG (SEQ ID NO: 2); andthe CDR3 includes an amino acid sequence represented by RVDGRVLSTIVVSYDY (SEQ ID NO: 3).The antibody is capable of binding to an intranuclear protein of an influenza virus.